2 型糖尿病血脂异常及其防治进展

www.yongyao.net　　2009-8-18 10:26:20　　来源：　　责任编辑：

分享到：

参考文献
[1] 王薇.糖尿病及其他心血管病危险因素关系的流行病学研究[J].国外医学内分泌分册，2005,24：附录1-1-1-2.
[2] 任琳，马山英，陈月华。糖尿病心血管并发症研究现状[J].国外医学内分泌分册，2005,25：213-214.
[3] 王吉耀.内科学[M].北京：人民卫生出版社，2001:969.
[4] 章庆红.我国各地糖尿病发病趋势[J].河北医药，2005,8；624.
[5] Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus（UKPDS:23）[J].BMJ,1998,316:823-828.
[6] Collins RM,Armitage J, Parish S, et al. Heart protection study of acholesterollowering with simvastin in 5963 people with diabetes; a randomized placebo，controlled trial[J]. Lancet,2003,361:2005-20.
[7] 邓正照.糖尿病脂代谢紊乱的调脂治疗[J].中国糖尿病杂志，2003；11（1）；71-74.
[8] Howard BV，Robbins DC，Sievers ML，et al.LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL：the Strong Heart Study[J].Arterioscler Thromb Vasc Biol，2000，20（30）：830.
[9] 吴鸿.2型糖尿病调脂治疗新理念与他汀类药物血管保护新认识[J].实用糖尿病杂志，2005；4；6-9.
[10] Austin MA, Breslow JL, Hennekens CH, et al. Lowdensity lipoprotein subclass patterns and risk of myocardial infarction[J]. JAMA,1988,260（13）:1917-1921.
[11] 陶军，周舸.高甘油三酯血症对动脉弹性功能的影响[J].心脑血管病防治，2003；3（4）:19.
[12] 赵晓娟.2型糖尿病的调脂治疗策略与评价.中国实用内科杂志，2004,3:24.
[13] Haffer SM, American Diabetes Association. Dyslipidemia management in adults with diabetes[J]. Diabetes Care,2004,27（Suppl 1）:S68-S71.
[14] De Backer G, Ambrosioni E, Borch-Johnsen K, et al.Executive Summary. European guideline on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical
practice[J]. Eur Heart J,2003,24:1601-1610.
[15] Grundy SM，Cleeman JI，Merz NB， et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel 3 guidelines[J].
Circulation,2004,110:227-239.
[16] ADA.Diabetes care.Jam,2001,24（suppl 1）:S58-S61.
[17] Pyorala K, Pederson TR, Kjekshus J, et al. For the Scandinavian Simvastalin Survival Study: cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the scandinavian Survival Study（4S）[J]. Diabetes Care,1997,20:614-620.
[18] Colhon HM, Betteridge DJ, Durrington PN, et al.Primary prevention of cardiovascular disease with atorvastain in type 2 diabetes in the Collaborstive AtoRvastatin Diabetes Study（CARDS）：a multicentre randomized placebo-controlled trail[J]. Lancet,2004,110:227-239.
[19] Pan J, Vand JT, Chan E, et al. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein in diabetes[J]. Metabolism,2002,51:1120-1127.
[20] Ridker PM, Canon CP, Morrow, et al. C-reactive protein levels and outcomes after statin therapy[J]. N Engl JMed,2005,352:20-28.
[21] 陈新谦.新编药物学[M].第15版.北京：人民卫生出版社，2002，383-385.
[22] Steiner G, Stewart D, Hosking JD. Baseline characteristics of the study population in the diabetes Atheroscerosis Intervention Study（DAIS）.World Health Organization Collabrating Centre for the Study of Atherosclerosis in Diabetes[J]. Am J Cardiol,1999,84（9）:1004-1010.
[23] Bloomfield RH, Savenport J, Babikian V, et al.Reductuon in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the veterans affairs HDL intervention trial（VA-HIT）[J]. Circulation,2001,103（23）:2828-2833.